Effect of Liver Disease on Pharmacokinetics

Principles of Clinical Pharmacology

Volumn , Issue , 2007, Pages 73-87

  Susla, Gregory M ^a   Atkinson, Arthur J ^b  

^a VHA Consulting Services   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77956803624     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012369417-1/50047-X     Document Type: Chapter

References (71)

1. Rowland M, Benet LZ, Graham GG. Clearance concepts in pharmacokinetics. J Pharmacokinet Biopharm 1973, 1:370-380.
2. Wilkinson GR, Shand DG. A physiological approach to hepatic drug clearance. Clin Pharmacol Ther 1975, 18:1178-1179.
3. Rane A, Wilkinson GR, Shand DG. Prediction of hepatic extraction ratio from in vitro measure-ment of intrinsic clearance. J Pharmacol Exp Ther 1977, 200:1744-1752.
4. Roberts MS, Donaldson JD, Rowland M. Models of hepatic elimination: Comparison of stochastic models to describe residence time distributions to predict the influence of drug distribution enzyme h. J Pharmacokinet Biopharm 1988, 16:123-136.
5. Roberts MS, Magnusson BM, Burczynski FJ, Weiss M. Enterohepatic circulation: Physiological pharmacoki-netic and clinical implications. Clin Pharmacokinet 2002, 41:377-390.
6. Rollins DE, Klaassen CD. Biliary excretion of drugs in man. Clin Pharmacokinet 1979, 4:420-424.
7. Heggie GD, Sommadossi J-P, Cross DS, Huster WJ, Diasio RB. Clinical pharmacokinetics of 5-fluorouracil its metabolites in plasma urine and bile. Cancer Res 1987, 47:41-83.
8. Siegers C-P, Bumann D. Clinical significance of the biliary excretion of drugs. Prog Pharmacol Clin Phar-macol 1991, 8:751-790.
9. Duggan DE, Hooke KF, Noll RM, Kwan KC. Enterohepatic circulation of indomethacin and its role in intestinal irritation. Biochem Pharmacol 1975, 24:368-379.
10. Veng Pedersen P, Miller R. Pharmacokinetics and bioavailability of cimetidine in humans. J Pharm Sci 1980, 69:2203-2206.
11. Miller R. Pharmacokinetics and bioavailability of ran-itidine in humans. J Pharm Sci 1984, 73:537-549.
12. Blaschke TF, Meffin PJ, Melmon KL, Rowland M. Influence of acute viral hepatitis on phenytoin kinetics and protein binding. Clin Pharmacol Ther 1975, 17:1749-1754.
13. Williams RL, Blaschke TF, Meffin PJ, Melmon KL, Rowland M. Influence of acute viral hepatitis on disposition and plasma binding of tolbutamide. Clin Pharmacol Ther 1977, 21:394-398.
14. Williams RL, Schary WL, Blaschke TF, Meffin PJ, Melmon KL, Rowland M. Influence of acute viral hepatitis on disposition and pharmacologic effect of warfarin. Clin Pharmacol Ther 1976, 20:1376-1379.
15. Williams RL, Blaschke TF, Meffin PJ, Melmon KL, Rowland M. Influence of viral hepatitis on the dispo-sition of two compounds with high hepatic clearance: Lidocaine and indocyanine green. Clin Pharmacol Ther 1976, 20:685-691.
16. sAg-positive chronic liver disease. Dig Dis Sci 1987, 32:301-309.
17. Prescott LF, Wright N. The effects of hepatic renal damage on paracetamol metabolism and excre-tion following overdosage. A pharmacokinetic study. Br J Pharmacol 1973, 49:90-97.
18. Sotaniemi EA, Niemelä O, Risteli L, Stenbäck F, Pelkonen RO, Lahtela JT, Risteli J. Fibrotic process and drug metabolism in alcoholic liver disease. Clin Pharmacol Ther 1986, 40:290-299.
19. Boyer TD, Henderson JM Portal hypertension and bleeding esophageal varices. Hepatology: A textbook of liver disease 2003, 710-714. WB Saunders, Philadelphia. 4th ed. Z. D, B. TD (Eds.).
20. Iwasa M, Nakamura K, Nakagawa T, Watanabe S, Katoh H, Kinosada Y, Maeda H, Habara J, Suzuki S. Single photon emission computed tomography to determine effective hepatic blood flow and intrahe-patic shunting. Hepatology 1995, 21:602-613.
21. Lebrec D, Kotelanski B, Cohn JN. Splanchnic hemody-namics in cirrhotic patients with esophageal varices and gastrointestinal bleeding. Gastroenterology 1976, 70:46-55.
22. Huet P-M, Villeneuve J-P. Determinants of drug disposition in patients with cirrhosis. Hepatology 1983, 3:581-629.
23. McLean A, du Souich P, Gibaldi M. Noninvasive kinetic approach to the estimation of total hepatic blood flow and shunting in chronic liver disease-a hypothesis. Clin Pharmacol Ther 1979, 25:359-365.
24. Neal EA, Meffin PJ, Gregory PB, Blaschke TF. Enhanced bioavailability and decreased clearance of analgesics in patients with cirrhosis. Gastroenterology 1979, 77:1108-1111.
25. Wood AJJ, Kornhauser DM, Wilkinson GR, Shand DG, Branch RA. The influence of cirrhosis on steady-state blood concentrations of unbound propran-olol after oral administration. Clin Pharmacokinet 1978, 3:913-918.
26. Blaschke TF. Protein binding and kinetics of drugs in liver diseases. Clin Pharmacokinet 1977, 2:161-166.
27. Guengerich FP, Turvy CG. Comparison of levels of several human microsomal cytochrome P-450 enzymes and epoxide hydrolase in normal and disease states using immunochemical analysis of. J Pharmacol Exp Ther 1991, 256:96-102.
28. George J, Murray M, Byth K, Farrell GC. Differential alterations of cytochrome P450 proteins in livers from patients with severe chronic liver disease. Hepatology 1995, 21:478-487.
29. Adedoyin A, Arns PA, Richards WO, Wilkinson GR, Branch RA. Selective effect of liver disease on the activ-ities of specific metabolizing enzymes: Investigation of cytochromes P450 2C19 and 2D6. Clin Pharmacol Ther 1998, 64:32-44.
30. Hasselström J, Eriksson S, Persson A, Rane A, Svensson O, Säwe J. The metabolism and bioavailabil-ity of morphine in patients with severe liver cirrhosis. Br J Clin Pharmacol 1990, 29:1189-1194.
31. Pugh RNH, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesoph-agus for bleeding oesophageal varices. Br J Surg 1973, 60:120-128.
32. CDER, CBER Pharmacokinetics in patients with impaired hepatic function: Study design, data anal-ysis, and impact on dosing and labeling. Guidance for industry 2003, Internet at, FDA, Rockville, MD. http://www.fda.gov/cder/guidance/index.htm.
33. Wood AJJ, Villeneuve JP, Branch RA, Rogers LW, Shand DG. Intact hepatocyte theory of impaired drug metabolism in experimental cirrhosis in the rat. Gastroenterology 1979, 76:8-17.
34. Tucker GT. Alteration of drug disposition in liver impairment. Br J Clin Pharmacol 1998, 46:355.
35. Bergquist C, Lindergard J, Salmonson T. Dosing rec-ommendations in liver disease. Clin Pharmacol Ther 1999, 66:289-297.
36. Engel G, Hofmann U, Heidemann H, Cosme J, Eichelbaum M. Antipyrine as a probe for human oxidative drug metabolism: Identifica-tion of the cytochrome P450 enzymes catalyzing 4-hydroxyantipyrine 3-hydroxymethylantipy. Clin Pharmacol Ther 1996, 59:646-649.
37. Herold C, Heinz R, Niedobitek G, Schneider T, Hahn EG, Schuppan D. Quantitative testing of liver function in relation to fibrosis in patients with chronic hepatitis B and C. Liver 2001, 21:1358-1362.
38. Testa R, Caglieris S, Risso D, Arzani L, Campo N, Alvarez S, Giannini E, Lantieri PB, Celle G. Monoethyl-glycinexylidide formation measurement as a hepatic function test to assess severity of chronic liver disease. Am J Gastroenterol 1997, 92:355.
39. Orlando R, Piccoli P, De Martin S, Padrini R, Floreani M, Palatini P. Cytochrome P50 1A2 is a major determinant of lidocaine metabolism in vivo: Effects of liver function. Clin Pharmacol Ther 2004, 75:201-204.
40. Lown K, Kolars J, Turgeon K, Merion R, Wrighton SA, Watkins PB. The erythromycin breath test selectively measures P450IIIA in patients with severe liver dis-ease. Clin Pharmacol Ther 1992, 51:613-623.
41. Breimer DD, Schellens JHM. A ' cocktail ' strategy to assess in vivo oxidative drug metabolism in humans. Trends Pharmacol Sci 1990, 11:260-265.
42. Frye RF, Matzke GR, Adedoyin A, Porter JA, Branch RA. Validation of the five-drug "Pitts-burgh cocktail" approach for assessment of selective regulation of drug-metabolizing enzymes. Clin Phar-macol Ther 1997, 62:2268-2273.
43. Tanaka E, Kurata N, Yasuhara H. How useful is the" cocktail approach" for evaluating human hepatic drug metabolizing capacity using cytochrome P450 phenotyping probes in vivo?. J Clin Pharm Ther 1903, 28:80-88.
44. Ginès P, Guevara M, Arroyo V, Rodés J. Hepatorenal syndrome. Liver 2003, 362:229-238.
45. Ginès A, Escorsell A, Ginès P, Saló J, Jiménez W, Inglada L, Navasa M, Clària J, Mimola A, Arroyo V, Rodés J. Incidence predictive factors and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 1993, 105:223-225.
46. Papadakis MA, Arieff AI. Unpredictability of clinical evaluation of renal function in cirrhosis: Prospective study. Am J Med 1987, 82:365-376.
47. Hoffman TA, Cestero R, Bullock WE. Pharmacody-namics of carbenicillin in hepatic and renal failure. Ann Intern Med 1970, 73:157-165.
48. Green L, Dick JD, Goldberger SP, Anelopulos CM. Prolonged elimination of piperacillin in a patient with renal and liver failure. Drug Intell Clin Pharm 1985, 19:1819-1827.
49. Cooper BE, Nester TJ, Armstrong DK, Dasta JF. High serum concentrations of mezlocillin in a critically ill patient with renal and hepatic dysfunction. Clin Pharm 1986, 5:229-236.
50. Ferenci P, Grimm G, Meryn S, Gangl A. Successful long-term treatment of portal-systemic encephalopa-thy by the benzodiazepine antagonist flumazenil. Gastroenterology 1989, 96:945-952.
51. Branch RA, Morgan MH, James J, Read AE. Intra-venous administration of diazepam in patients with chronic liver disease. Gut 1976, 17:173-178.
52. Bakti G, Fisch HU, Karlaganis G, Minder C, Bircher J. Mechanism of the excessive sedative response of cir-rhotics to benzodiazepines: Model experiments with triazolam. Hepatology 1987, 7:427-429.
53. Schentag JJ, Cerra FB, Calleri GM, Leising ME, French MA, Bernhard H. Age disease and cimeti-dine disposition in healthy subjects and chronically ill patients. Clin Pharmacol Ther 1981, 29:764-766.
54. Brater DC. Resistance to loop diuretics: Why it happens and what to do about it. Drugs 1985, 30:240-243.
55. Brater DC. Use of diuretics in cirrhosis and nephrotic syndrome. Semin Nephrol 1999, 19:975-983.
56. Naranjo CA, Pontigo E, Valdenegro C, González G, Ruiz I, Busto U. Furosemide-induced adverse reac-tions in cirrhosis of the liver. Clin Pharmacol Ther 1979, 25:629-638.
57. Westphal J-F, Brogard J-M. Drug administration in chronic liver disease. Drug Safety 1997, 17:737-743.
58. Daskalopoulos G, Pinzani M, Murray N, Hirschberg R, Zipser RD. Effects of captopril on renal function in patients with cirrhosis and ascites. J Hepatol 1987, 4:427-443.
59. Rodighiero V. Effects of liver disease on pharmacokinetics: An update. Clin Pharmacokinet 1999, 37:575-580.
60. Lee JT, Yee Y-G, Dorian P, Kates RE. Influence of hepatic dysfunction on the pharmacokinetics of propafenone. J Clin Pharmacol 1987, 27:154-160.
61. Somogyi A, Albrecht M, Kliems G, Schäfer K, Eichelbaum M. Pharmacokinetics bioavailability and ECG response of verapamil in patients with liver cirrhosis. Br J Clin Pharmacol 1981, 12:47-73.
62. Kleinbloesem CH, van Harten J, Wilson JPH, Danhof M, van Brummelen P, Breimer DD. Nifedipine: Kinetics and hemodynamic effects in patients with liver cirrhosis after intravenous and oral administration. Clin Pharmacol Ther 1986, 40:330-336.
63. Dylewicz P, Kirch W, Santos SR, Hutt HJ, Mönig H, Ohnhaus EE. Bioavailability and elimination of nitrendipine in liver disease. Eur J Clin Pharmacol 1987, 32:399-431.
64. van Harten J, van Brummelen P, Wilson JHP, Lodewijks MTM, Breimer DD. Nisoldipine: Kinetics and effects on blood pressure in patients with liver cir-rhosis after intravenous and oral administration. Eur J Clin Pharmacol 1988, 34:384-389.
65. Lo M-W, Goldberg MR, McCrea JB, Lu H, Furtek CI, Bjornsson TD. Pharmacokinetics of losartan an angiotensin II receptor antagonist and its active metabolite EXP3174 in humans. Clin Pharmacol Ther 1995, 58:51-60.
66. Goa KL, Wagstaff AJ. Losartan potassium. A review of its pharmacology clinical efficacy and tolerability in the management of hypertension. Drugs 1996, 51:21-28.
67. McIntyre M, Caffe SE, Michalak RA, Reid JL. Losartan an orally active angiotensin (AT1) receptor antagonist: A review of its efficacy and safety in essential hypertension. Pharmacol Ther 1997, 74:563-568.
68. 14C]omeprazole in patients with liver cirrhosis. Clin Pharmacokinet 1993, 24:387-394.
69. Venkataramanan R, Jain A, Cadoff E, Warty V, Iwasaki K, Nagase K, Drajack A, Imventarza O, Todo S, Fung JJ, Starzl TE. Pharmacokinetics of FK 506: Preclinical and clinical studies. Transplant Proc 1990, 22(suppl 1):641-649.
70. Jain AB, Venkataramanan R, Cadoff E, Fung JJ, Todo S, Krajack A, Starzl TE. Effect of hepatic dys-function and T tube clamping on FK 506 pharma-cokinetics and trough concentrations. Transplant Proc 1990, 22(suppl 1):820-845.
71. Schneider AW, Kalk JF, Klein CP. Effect of losartan angiotensin II receptor antagonist on portal pres-sure in cirrhosis. Hepatology 1999, 29:181-194.